pharma · Myelodysplastic Syndromes (MDS) · Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
Taiho Pharma Canada
Taiho Pharma Netherlands B.V.
Taiho Pharma Netherlands is a pharma organization headquartered in EU. Primary therapeutic focus areas include Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Sol
2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA HQ
2017 Founded
13 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA
- Founded
- 2017
- Employees
- 13
- Programs
- 16
- Drugs
- 30
- Patents
- 0
TAS6417-301
Phase 3 · small molecule · Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
TAS6417-301 for Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations is a Phase 3 program (small_molecule) at Taiho Pharma Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code TAS6417-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Taiho Pharma Netherlands B.V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
- Status
- active
- Trials
- 1